期刊文献+

80例晚期小细胞肺癌的化疗方案探讨

下载PDF
导出
摘要 目的:探讨涤痰方联合EP方案治疗晚期小细胞肺癌的临床疗效和毒副作用。方法:本组一共80例小细胞肺癌患者,随机平分为两组,治疗组和对照组各40例,两组都采用相同的足叶乙甙+DDP方案化疗,1个月为一个疗程,治疗组在应用化疗的同时加用涤痰方(姜半夏、胆南星各8g,橘红、茯苓、枳实各6g,人参、菖蒲各3g,竹茹2g,甘草1.5g)加生姜、大枣,水煎分服。结果:治疗组和对照组在临床疗效上无显著性差异(P>0.05),但是治疗组患者的血生化指标和消化道的不良反应及肺部的咯痰咯血发生率要明显好于对照组(P<0.05),有显著性差异。结论:涤痰方联合EP方案治疗晚期小细胞肺癌可减少化疗对患者的各种毒副作用,提高化疗耐受性,提高患者生活质量。
作者 吴大广
出处 《医学信息(中旬刊)》 2011年第2期441-442,共2页 Medical Information Operations Sciences Fascicule
  • 相关文献

参考文献3

二级参考文献61

  • 1[1]Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst,1991,83(12)∶855-861.
  • 2[2]Roth BJ,Johnson DH, Einhorn LH,et al.Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer:a phase Ⅲ trial of the Southeastern Cancer Study Group.J Clin Oncol,1992,10(2)∶282.
  • 3[3]Feld R, Evans WK, Coy P, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol,1996,5(9)∶1401-1409.
  • 4[4]Postmus PE, Scagliotti G, Groen HJ, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase Ⅲ trial. Eur J Cancer,1996,32A(9)∶1498-1503.
  • 5[5]Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Can-cer Cooperative Group. J Clin Oncol,1993,11(7)∶1230-1240.
  • 6[6]Bleehen NM, Fayers PM, Girling DJ, et al. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J cancer,1994,59(2)∶584.
  • 7[7]Bleehen NM, Girling DJ, Machin D, et al. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). Ⅱ: quality of life. Medical Research Council Lung Cancer Working Party. Br J Cancer,1993,68(6)∶1157-1166.
  • 8[8]Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol,1994,12(10)∶2022-2034.
  • 9[9]Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med,1993,329(25)∶1848-1852.
  • 10[10]Groen HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol,1999,17(3)∶927-932.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部